Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia

AstraZeneca85 enrolled

Overview

The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients with schizophrenia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Schizophrenia

Interventions

Quetiapine fumarateDRUG

oral

conventional treatment for schizophreniaDRUG

various standard therapies

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Documented clinical diagnosis of schizophrenia or schizoaffective disorder for at least 2 years. * Clinically stable and in an outpatient setting before entering the study (visit 1). Exclusion Criteria: * Use of clozapine and quetiapine within two months prior to visit 1. * If total points are ≤ 55 Intelligence quotient (IQ) according to score of WAIS-III test at visit 1.

Locations (15)

Research Site

Eskilstuna, Sweden

Research Site

Gothenburg, Sweden

Research Site

Hisingsbacka, Sweden

Outcomes

Primary Outcomes

Social outcome measured by Strauss-Carpenter scale

Time frame: change from baseline to last visit and end of CRT

Secondary Outcomes

Change in PANSS total score

Time frame: change from baseline to visit 2, from baseline to end of CRT and from baseline to last visit

Change in PANSS positive, negative and general psychopathology symptom subscales

Time frame: change from baseline to visit 2, from baseline to end of CRT and from baseline to last visit

Change in cognition as measured by a Cognitive Battery of Tests

Time frame: change from baseline to end of CRT and from baseline to last visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.